Source: Annual Congress 2004 - Chemotherapy, targeted therapies costs and outcomes
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
A. Dirican, S. Findik, O. Uzun, A. Atici, L. Erkan (Kurupelit, Turkey). Stage IIIB and stage IV non-small cell lung cancers; responses to treatment and survival durations. Eur Respir J 2004; 24: Suppl. 48, 1944

Member's Comments

No comment yet.

Related content which might interest you: Treatment tolerance and survival in elderly patients with stage IV non-small cell lung cancer (NSCLC) Source: International Congress 2019 – Symptoms, risks, complications and palliative care in thoracic oncology Year: 2019 Analysis of prognostic factors in patients with stage IIIB, IV non-small cell lung cancer Source: Annual Congress 2010 - Staging of lung cancer Year: 2010 Radiotherapy for stage III non-small cell lung cancer (NSCLC) Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 Management of locally advanced nonsmall cell lung cancer Source: Eur Respir Mon; 2009: 44: 260–270 Year: 2009 Analysis of survival and characteristics of patients with non-small cell lung carcinoma (NSCLC) stage IV depending on molecular markers Source: International Congress 2019 – Biology and prognosis of lung cancer Year: 2019 Validity of predictive estimate by physicians of the survival of patients with recently diagnosed stages IIIB and IV non-small cells lung cancer (NSCLC) Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology Year: 2007 Use of adjuvants to chemotherapy in stage IV nonsmall cell lung carcinoma (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 64s Year: 2003 The treatment of stage IV non-small cell lung cancer with target therapies Source: Annual Congress 2013 –Which treatment other than chemotherapy for stage IV NSCLC? Year: 2013 Survival impact of surgery in the treatment of stage IIIB-IVA non-small cell lung cancer Source: International Congress 2018 – Lung cancer: personalised medicine Year: 2018 FEV1 is not a prognostic marker in operated patients with stage I or II non-small cell lung cancer (NSCLC) Source: Annual Congress 2011 - Surgery for lung cancer: pre-operative evaluation and results Year: 2011 NSCLC stage IV Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 Treatment of early (stage I/II) non-small cell lung cancer Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment Year: 2005 Prognostic factors in patients with resected pathologic stage I and II nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 269s Year: 2002 Management of stage I and II nonsmall cell lung cancer Source: Eur Respir J 2017; 49(1): 1600764; DOI: 10.1183/13993003.00764-2016 Year: 2017 Selective adjuvant chemotherapy according to in-vitro chemoresistance test: Long term follow up of patients with resectable non-small cell lung cancer (NSCLC) stage IIIA Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 Stage IIIA-N2 non-small cell lung cancer (NSCLC): comparison of prognostic factors in 257 patients treated with surgery (S) versus induction chemotherapy plus surgery (IC+S) Source: Eur Respir J 2002; 20: Suppl. 38, 597s Year: 2002 Surgical multimodality treatment for stage III non-small cell lung cancer (NSCLC) Source: Annual Congress 2006 - Integrative approaches for stage III non-small cell lung cancer Year: 2006 Prognostic factors in pathological stage IB nonsmall cell lung cancer greater than 3 cm Source: Eur Respir J 2010; 36: 1355-1361 Year: 2010